Skip to main
OTLK

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics is a clinical-stage biopharmaceutical company with a promising monoclonal antibody product pipeline and a recently approved FDA product, LYTENAVA, for wet age-related macular degeneration (wAMD) treatment. The company has a solid commercial launch plan in place for LYTENAVA, with a lean sales force model and strong market potential. Additionally, LYTENAVA's differentiated profile, with higher manufacturing standards and potential pricing and reimbursement advantages, positions the company for success and potential revenue of over $500M by 2030. With a recent FDA approval and a strong commercialization strategy, Outlook Therapeutics presents a compelling investment opportunity in the biotechnology sector.

Bears say

Outlook Therapeutics is facing significant risks with their ONS-5010 product, including the potential for disrupted sales due to changes in the availability of repackaged bevacizumab. Despite management's optimistic projections, there is still significant uncertainty surrounding their potential peak sales of $500M by 2030. Furthermore, the recent FDA appeal win does not guarantee a positive outcome for the product's approval, and the company is also facing financial and regulatory risks that could impact their ability to successfully bring their product to market.

OTLK has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 4 analysts, OTLK has a Buy consensus rating as of Aug 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.